Overexpression of peptidylarginine deiminase IV features in apoptosis of haematopoietic cells

Apoptosis

Volumn 11, Issue 2, 2006, Pages 183-196

  Liu, G Y ^a   Liao, Y F ^b   Chang, W H ^a   Liu, C C ^a   Hsieh, M C ^a   Hsu, P C ^c   Tsay, G J ^d   Hung, H C ^b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c Da Chien General Hospital   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Bax; Bcl 2; p21; p53; PADI4; PADIs

Indexed keywords

CASPASE 3; CASPASE 9; CYCLIN D; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYTOCHROME C; DNA FRAGMENT; MITOCHONDRIAL ENZYME; PROTEIN ARGININE DEIMINASE; PROTEIN ARGININE DEIMINASE 4; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; APOPTOSIS; ARTICLE; BIOACCUMULATION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOPLASM; DOSE TIME EFFECT RELATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME RELEASE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; UPREGULATION;

APOPTOSIS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HL-60 CELLS; HUMANS; HYDROLASES; JURKAT CELLS; MEMBRANE POTENTIALS; MITOCHONDRIA; T-LYMPHOCYTES;

EID: 33344477322     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10495-006-3715-4     Document Type: Article

References (55)

1. Guerrin M, Ishigami A, Mechin MC, et al. cDNA cloning, gene organization and expression analysis of human peptidylarginine deiminase type I. Biochem J 2003; 370: 167-174
2. Ishigami A, Ohsawa T, Asaga H, Akiyama K, Kuramoto M, Maruyama N. Human peptidylarginme deiminase type II: Molecular cloning, gene organization, and expression in human skin. Arch Biochem Biophys 2002; 407: 25-31.
3. Kanno T, Kawada A, Yamanouchi J, et al. Human peptidylarginine deiminase type III: Molecular cloning and nucleotide sequence of the cDNA, properties of the recombinant enzyme, and immunohistochemical localization in human skin. J Invest Dermatol 2000; 115: 813-823.
4. Nakashima K, Hagiwara T, Ishigami A, et al. Molecular characterization of peptidylarginine deiminase in HL-60 cells induced by retinoic acid and 1alpha, 25-dihydroxyvitamin D(3). J Biol Chem 1999; 274: 27786-27792.
5. Chavanas S, Mechin MC, Takahara H, et al. Comparative analysis of the mouse and human peptidylarginine deiminase gene clusters reveals highly conserved non-coding segments and a new human gene, PADI6. Gene 2004; 330: 19-27.
6. Nijenhuis S, Zendman AJ, Vossenaar ER, Pruijn GJ, van Venrooij WJ. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta 2004; 350:17-34.
7. Chang X, Yamada R, Suzuki A, et al. Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 40-50.
8. Senshu T, Akiyama K, Ishigami A, Nomura K. Studies on specificity of peptidylarginine deiminase reactions using an immunochemical probe that recognizes an enzymatically deiminated partial sequence of mouse keratin K1. J Dermatol Sci 1999; 21: 113-126.
9. Ishida-Yamamoto A, Senshu T, Eady RA, et al. Sequential reorganization of cornified cell keratin filaments involving filaggrin-mediated compaction and keratin 1 deimination. J Invest Dermatol 2002; 118: 282-287.
10. Tarcsa E, Marekov LN, Mei G, Melino G, Lee SC, Steinert PM. Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin. J Biol Chem 1996; 271: 30709-30716.
11. Vossenaar ER, Despres N, Lapointe E, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004; 6: R142-R150.
12. Moscarello MA, Wood DD, Ackerley C, Boulias C. Myelin in multiple sclerosis is developmentally immature. J Clin Invest 1994; 94: 146-154.
13. Wang Y, Wysocka J, Sayegh J, et al. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 2004; 306: 279-283.
14. Cuthbert GL, Daujat S, Snowden AW, et al. Histone deimination antagonizes arginine methylation. Cell 2004; 118:545-553.
15. Vossenaar ER, Nijenhuis S, Helsen MM, et al. Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2489-2500.
16. Caponi L, Petit-Teixeira E, Sebbag M, et al. A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population. Ann Rheum Dis 2005; 64: 587-593.
17. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001; 166: 4177-4184.
18. Suzuki A, Yamada R, Ohtake-Yamanaka M, Okazaki Y, Sawada T, Yamamoto K. Anti-citrullinated collagen type I antibody is a target of autoimmunity in rheumatoid arthritis. Biochem Biophys Res Commun 2005; 333: 418-426.
19. Wood DD, Bilbao JM, O'Connors P, Moscarello MA. Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann Neurol 1996; 40: 18-24.
20. Wright PW, Bolling LC, Calvert ME, et al. ePAD, an oocyte and early embryo-abundant peptidylarginine deiminase-like protein that localizes to egg cytoplasmic sheets. Dev Biol 2003; 256: 73-88.
21. Asaga H, Yamada M, Senshu T. Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages. Biochem Biophys Res Commun 1998; 243: 641-646.
22. Mizoguchi M, Manabe M, Kawamura Y, et al. Deimination of 70-kD nuclear protein during epidermal apoptotic events in vitro. J Histochem Cytochem 1998; 46: 1303-1309.
23. Senshu T, Akiyama K, Nagata S, Watanabe K, Hikichi K. Peptidylargmine deiminase in rat pituitary: Sex difference, estrous cycle-related changes, and estrogen dependence. Endocrinology 1989; 124: 2666-2670.
24. Okuda M. The role of nucleophosmin in centrosome duplication. Oncogene 2002; 21: 6170-6174.
25. Hingorani K, Szebeni A, Olson MO. Mapping the functional domains of nucleolar protein B23. J Biol Chem 2000; 275: 24451-24457.
26. Takemura M, Ohoka F, Perpelescu M, et al. Phosphorylation-dependent migration of retinoblastoma protein into the nucleolus triggered by binding to nucleophosmin/B23. Exp Cell Res 2002; 276: 233-241.
27. Hagiwara T, Nakashima K, Hirano H, Senshu T, Yamada M. Deimination of arginine residues in nucleophosmin/B23 and histones in HL-60 granulocytes. Biochem Biophys Res Commun 2002; 290: 979-983.
28. Hagiwara T, Hidaka Y, Yamada M. Deimination of histone H2A and H4 at argmine 3 in HL-60 granulocytes. Biochemistry 2005; 44: 5827-5834.
29. Liu GY, Hung YC, Hsu PC, et al. Ornithine decarboxylase prevents tumor necrosis factor alpha-induced apoptosis by decreasing intracellular reactive oxygen species. Apoptosis 2005; 10: 569-581.
30. Boyde TR, Rahmatullah M. Optimization of conditions for the colorimetric determination of citrulline, using diacetyl monoxime. Anal. Biochem. 1980; 107: 424-431.
31. Huang HH, Hsu PC, Hung YC et al. Ornithine decarboxylase prevents methotrexate-induced apoptosis by reducing intracellular reactive oxygen species production. Apoptosis 2005; 10: 895-907.
32. Lum JJ, Bauer DE, Kong M, et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005; 120: 237-248.
33. Levine B. Eating oneself and uninvited guests: Autophagy-related pathways in cellular defense. Cell 2005; 120: 159-162.
34. Vossenaar ER, Radstake TR, van der Heijden A, et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 2004; 63: 373-381.
35. 2+-dependent deimination-induced disassembly of intermediate filaments involves specific modification of the amino-terminal head domain. J Biol Chem 1989; 264: 18119-18127.
36. Arita K, Hashimoto H, Shimizu T, Nakashima K, Yamada M, Sato M. Structural basis for Ca(2+)-induced activation of human PAD4. Nat Struct Mol Biol 2004; 11: 777-783.
37. Nakashima K, Hagiwara T, Yamada M. Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes. J Biol Chem 2002; 277: 49562-49568.
38. Kastan MB, Zhan Q, el-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-597.
39. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-849.
40. Woodworth CD, Wang H, Simpson S, Alvarez-Salas LM, Notario V. Overexpression of wild-type p53 alters growth and differentiation of normal human keratinocytes but not human papillomavirus-expressing cell lines. Cell Growth Differ 1993; 4: 367-376.
41. Weinberg WC, Azzoli CG, Chapman K, Levine AJ, Yuspa SH. p53-mediated transcriptional activity increases in differentiating epidermal keratinocytes in association with decreased p53 protein. Oncogene 1995; 10: 2271-2279.
42. Hall PA, McKee PH, Menage HD, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993; 8: 203-207.
43. Berg RJ, van Kranen HJ, Rebel HG, et al. Early p53 alterations in mouse skin carcinogenesis by UVB radiation: immunohistochemical detection of mutant p53 protein in clusters of preneoplastic epidermal cells. Proc Natl Acad Sci USA 1996; 93: 274-278.
44. Li G, Mitchell DL, Ho VC, Reed JC, Tron VA. Decreased DNA repair but normal apoptosis in ultraviolet-irradiated skin of p53-transgenic mice. Am J Pathol 1996; 148: 1113-1123.
45. Appella E, Anderson CW. Signaling to p53: Breaking the post-translational modification code. Pathol Biol (Paris) 2000; 48: 227-245.
46. Munoz-Alonso MJ, Acosta JC, Richard C, Delgado MD, Sedivy J, Leon J. p21Cip1 and p27Kip1 induce distinct cell cycle effects and differentiation programs in myeloid leukemia cells. J Biol Chem 2005; 280: 18120-18129.
47. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-1512.
48. Gilmour SK, Birchler M, Smith MK, Rayca K, Mostochuk J. Effect of elevated levels of ornithine decarboxylase on cell cycle progression in skin. Cell Growth Differ 1999; 10: 739-748.
49. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004; 23: 2797-2808.
50. Chao DT, Korsmeyer SJ. BCL-2 family: Regulators of cell death. Annu. Rev Immunol 1998; 16: 395-419.
51. Schuler M, Green DR. Transcription, apoptosis and p53: catch-22. Trends Genet 2005; 21: 182-187.
52. Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303: 1010-1014.
53. Byun Y, Chen F, Chang R, Trivedi M, Green KJ, Cryns VL. Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death Differ 2001; 8: 443-450.
54. Germain D, Russell A, Thompson A, Hendley J. Ubiquitination of free cyclin D1 is independent of phosphorylation on threonine 286. J Biol Chem 2000; 275: 12074-12079.
55. Newman RM, Mobascher A, Mangold U, et al. Antizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repression. J Biol Chem 2004; 279: 41504-41511.